Journal
PARASITOLOGY RESEARCH
Volume 102, Issue 5, Pages 825-833Publisher
SPRINGER
DOI: 10.1007/s00436-008-0887-6
Keywords
-
Categories
Funding
- NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012307] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071223] Funding Source: NIH RePORTER
- NCRR NIH HHS [P40-RR-12307] Funding Source: Medline
- NIAID NIH HHS [R01AI71223] Funding Source: Medline
Ask authors/readers for more resources
Considerable morbidity and mortality results from the affliction of an estimated 200 million people worldwide by several species of schistosomes; 779 million are exposed to the disease in 74 different countries. Even though anti-parasitic drugs and other control measures, including public hygiene and snail control are available, the advent of an effective vaccine still remains the most potentially powerful means for the control of this disease. The putative vaccine could be administered to small children prior to the time when their contact with infected water is maximal, so as to prevent severe infection in the subsequent years. This review attempts to summarize the status of schistosome vaccine development with special emphasis on functionally important vaccine candidates. The importance of utilizing both murine and nonhuman primate models as a prerequisite for clinical trials is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available